SUMMARY. If adenosine is the major factor responsible for myocardial metabolic vasodilation, its release should be sustained as long as oxygen consumption and coronary flow are augmented. To see if adenosine meets this criterion, we examined the time course of its release during norepinephrine infusion in isolated, non-working guinea pig hearts (n = 8). During an 11-minute infusion period (steady state perfusate concentration = 6 X 10" 8 M), the coronary effluent was collected over 30-second intervals for measurements of coronary flow (ml/min per g), and adenosine and inosine release (pmol/min per g). Myocardial oxygen consumption (MVO 2 = M' O 2 /min per g) was measured at 1, 4, 6.5, and 11 minutes. Control values of coronary flow, myocardial oxygen consumption, and adenosine and inosine release were 7.5 ± 0.4, 85 ± 5, 22 ± 5, and 431 ± 39, respectively. During norepinephrine infusion, coronary flow, myocardial oxygen consumption, and adenosine release attained maximal levels within one minute (inosine within 2 minutes). These values were 10.6 ± 0.4, 125 ± 9, 849 ± 110, and 2595 ± 581, respectively. Thereafter, coronary flow and myocardial oxygen consumption values were sustained. In contrast, adenosine and inosine release significantly declined to nadirs by 9.5 minutes. Thereafter, steady state levels were maintained at 117 ± 24 and 960 ± 294, respectively. Further, evaluation of this response shows first, that the coronary bed can dilate further with infusion of adenosine during norepinephrine infusion; second, that the myocardium releases more adenosine, in a phasic manner, if stimulated with higher concentrations of norepinephrine; third, that the release of adenosine is independent of a-receptor activation (i.e., same responses to norepinephrine occur with prazosin, or isoproterenol); fourth, that there is phasic release of adenosine during stimulation by elevated perfusate calcium concentration; and fifth, that the release of adenosine is dependent upon /3-receptor stimulation with catecholamines but not with elevated perfusate calcium. These results suggest that release of adenosine from myocardial cells peaks soon after metabolism is increased, and then wanes. This raises the possibility that adenosine does not maintain sustained metabolic coronary dilation. (Circ Res 53: 636-643, 1983) 
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SUMMARY. If adenosine is the major factor responsible for myocardial metabolic vasodilation, its release should be sustained as long as oxygen consumption and coronary flow are augmented. To see if adenosine meets this criterion, we examined the time course of its release during norepinephrine infusion in isolated, non-working guinea pig hearts (n = 8). During an 11-minute infusion period (steady state perfusate concentration = 6 X 10" 8 M), the coronary effluent was collected over 30-second intervals for measurements of coronary flow (ml/min per g), and adenosine and inosine release (pmol/min per g). Myocardial oxygen consumption (MVO 2 = M' O 2 /min per g) was measured at 1, 4, 6.5, and 11 minutes. Control values of coronary flow, myocardial oxygen consumption, and adenosine and inosine release were 7.5 ± 0.4, 85 ± 5, 22 ± 5, and 431 ± 39, respectively. During norepinephrine infusion, coronary flow, myocardial oxygen consumption, and adenosine release attained maximal levels within one minute (inosine within 2 minutes). These values were 10.6 ± 0.4, 125 ± 9, 849 ± 110, and 2595 ± 581, respectively. Thereafter, coronary flow and myocardial oxygen consumption values were sustained. In contrast, adenosine and inosine release significantly declined to nadirs by 9.5 minutes. Thereafter, steady state levels were maintained at 117 ± 24 and 960 ± 294, respectively. Further, evaluation of this response shows first, that the coronary bed can dilate further with infusion of adenosine during norepinephrine infusion; second, that the myocardium releases more adenosine, in a phasic manner, if stimulated with higher concentrations of norepinephrine; third, that the release of adenosine is independent of a-receptor activation (i.e., same responses to norepinephrine occur with prazosin, or isoproterenol); fourth, that there is phasic release of adenosine during stimulation by elevated perfusate calcium concentration; and fifth, that the release of adenosine is dependent upon /3-receptor stimulation with catecholamines but not with elevated perfusate calcium. These results suggest that release of adenosine from myocardial cells peaks soon after metabolism is increased, and then wanes. This raises the possibility that adenosine does not maintain sustained metabolic coronary dilation. (Circ Res 53: 636-643, 1983) MYOCARDIAL metabolism is the dominant factor influencing coronary blood flow in the normal heart. Adenosine production by myocardial cells may provide an important mechanism for coupling myocardial metabolism and coronary blood flow Belloni, 1979; Berne and Rubio, 1979; Berne, 1980; Mustafa, 1980) . Adenosine is a potent, receptor-mediated vasodilator Schrader et al., 1977a; Schrader, 1981) ; the coronary bed has been shown to respond to exogenously administered adenosine in a dose-related manner (Schrader et al., 1977b) . Furthermore, increased myocardial metabolism has been associated with parallel changes in (1) the adenosine concentration of coronary effluent (Katori and Berne, 1966; Schrader et al., 1977b; Fredholm et al., 1982) , (2) adenosine concentration of pericardial fluid (Watkinson et al., 1979; Miller et al., 1979; Bacchus et al., 1982) , (3) coronary adenosine release (Wiedmeier and Spell, 1977) , and (4) adenosine content of myocardial tissue samples (Foley et al., 1978; McKenzie et al., 1980; Saito et al., 1980; Jones et al., 1982) . However, these studies were not designed to give information on whether a steady state had been achieved. Thus, we do not know whether there is a positive relationship between steady state changes in coronary blood flow and any index of adenosine production.
Isolated, non-working guinea pig hearts were used to study the relationship between adenosine release and coronary vasodilation during increased myocardial metabolism. During norepinephrine infusion, adenosine release first increases dramatically, then declines to a much lower value, despite an elevated, unchanging coronary flow and oxygen consumption. A similar pattern of phasic adenosine release was obtained when metabolism was elevated by increasing the calcium concentration of the perfusate. We also studied the relative importance of a-and /9-receptor activation in the phasic adenosine release response. Our results demonstrate that areceptor activation is not responsible for the phasic nature of adenosine release, and that /3-receptor activation is necessary for release of adenosine dur-ing catecholamine stimulation but not in the response to calcium.
The phasic release of adenosine during steady state metabolic stimulation and elevated coronary flow suggest a major participation by at least one other coronary vasodilator under these experimental conditions.
Methods
The hearts of anesthetized (sodium pentabarbitol: 50 mg/kg, ip) guinea pigs (male, 250-300 g) were rapidly excised and immersed in ice-cold perfusate (NaCl: 117 mM; KC1: 4.7 mM; KH 2 PO 4 : 1.2 mM; MgSO 4 : 1.2 ITIM; NaHCO 3 : 21 mM; Na 2 -EDTA: 0.2 MM; CaCl 2 : 2.7 NUN; glucose: 8 mM; pyruvate: 2 mM). The aorta was cannulated and the heart perfused via retrograde aortic perfusion. All hearts were maintained in a nonworking state by venting the left ventricle via a catheter through the mitral valve. The perfusate was equilibrated with 95% oxygen + 5% carbon dioxide, continuously filtered through a 3-^m filter, maintained at 37°C and pH 7.4, and not recirculated. Perfusion pressure was maintained constant at 60 cm H 2 O. The pulmonary artery was cannulated for collection of the coronary effluent and determination of effluent partial pressure of oxygen (P02). Effluent P02 was measured either by sampling the pulmonary artery for determination with a blood gas analyzer or via an indwelling oxygen electrode (Instech laboratories, Oxygen Uptake System 102A). Perfusate Po? was determined before and immediately after the infusion periods. Coronary flow was determined by means of an electromagnetic flow probe in the aortic line and expressed as flow per gram of myocardium (wet weight). Myocardial oxygen consumption was expressed as jtl O 2 /min per g and was calculated according to the equation: MVO 2 = CF X (Pa-Pv) X c/760) where CF = coronary flow (ml/min per g wet weight), Pa-Pv = perfusate-coronary effluent difference in P02 (mm Hg), and c = Bunsen solubility coefficient of oxygen dissolved in perfusate at 37°C (23 //I O 2 /atm per ml perfusate) (Zander and Euler, 1976) .
Protocol
After a 20-minute equilibration period, coronary flow was measured and samples of perfusate and coronary effluent were collected for determination of control adenosine and inosine release. In addition, the Po? of the perfusate and coronary effluent were measured in order to determine the perfusate-venous oxygen difference. Norepinephrine was then infused (delivery rate: 6 X 10~1 0 mol/min) into the aortic cannula (1 cm above the heart) for 11 minutes. During the infusion period, the coronary effluent was continuously fractionated every 30 seconds for the first 3 minutes. Thirty-second fractions were subsequently taken at 6, 9, and 11 minutes. Effluent fractions were then analyzed for adenosine and inosine content (see Measurement of Purines), and the release of purines was calculated as the product of the effluent concentration and the mean coronary flow during the collecting period. During the infusion period, the Po 2 of the pulmonary artery effluent was measured at 1, 4, 6.5, and 11 minutes.
A second series of control experiments was designed to evaluate the conditions under which phasic release of adenosine could occur. Two experiments were designed to examine the conditions of the coronary vasculature and the availability of adenosine for release after 11 minutes 637 of norepinephrine infusion. In these experiments, we verified that phasic release of adenosine had occurred during norepinephrine infusion (6 X 10~1 0 mol/min) by collecting coronary effluent samples for 2 minutes beginning at 2, 5, and 9 minutes. Then we attepted to determine whether the coronary bed could dilate further, by infusing adenosine (1 X 10 mol/min) for 7 minutes, or if the myocardium could release more adenosine, by infusing a higher dose of norepinephrine (3 X 10~9 mol/min) for 11 minutes. Effluent samples were again taken over 2-minute intervals. A third experiment was performed to determine whether the large increase in adenosine release, seen initially with norepinephrine infusion, was due to the declining vascular concentration of norepinephrine that results from a constant delivery rate and an increasing coronary flow. During this protocol, hearts were exposed to perfusate containing norepinephrine in a concentration (6 X 10~8 mol/liter) equivalent to the steady state intracoronary concentration attained during norepinephrine infusion. Measurements of variables were made as described in the initial series.
A third series of experiments was designed to evaluate the relative contributions of a-and /9-receptor activation to the release of adenosine during norepinephrine stimulation. After equilibration, we exposed hearts to the following protocols: (1) a-receptor blockade for 20 minutes with prazosin (delivery rate: 3 X 10~8 mol/min), followed by 11-minute infusion of norepinephrine (6 X 10~'° mol/ min); (2) 11-minute infusion of isoproterenol (3 X 10 mol/min); and (3) jS-receptor blockade for 5 minutes with propranolol (7 X 10" 8 mol/min), followed by 11-minute infusion of norepinephnne (6 X 10~1 0 mol/min). In protocols 1 and 3, infusion of receptor-blocking drugs was continued during infusion of norepinephrine. Adequate «-receptor blockade was demonstrated by elimination of the initial vasoconstrictor response to infusion of norepinephrine. /9-Receptor blockade was demonstrated by abolition of any response to infusion of isoproterenol (same infusion rate as in protocol 2). Measurements of variables were made as described in the initial series except for measurement of P02 (see Figs. 2 and 3 for details).
The final series of experiments was designed to evaluate the generality of the phasic release of adenosine during positive inotropic intervention and the importance of /Sreceptor activation. After equilibration (CaCl 2 concentration: 2.7 mM), hearts were exposed to perfusate containing 8.1 mM CaCl 2 for 11 minutes, or /J-receptor blockade with propranolol (delivery rate: 7 X 10~8 mol/min) for 5 minutes prior to as well as during exposure to 8.1 mM CaCl 2 . Measurements of variables were made as described in the previous series.
Measurement of Purines
Samples of coronary effluent (30-second fractions, except where noted) were frozen and stored at -90°C. Samples were thawed within 5 days, evaporated, and redissolved in 400 /il ultra-pure distilled water (Milli-Q water, Millipore, Inc.) The undissolved salts were separated by centrifugation, and the supernatant was assayed for adenosine and inosine by high performance liquid chromatography (HPLC). Two pumps (Waters model 6000A and M-45) were programmed (Waters System Controller) for gradient elurion of 200 p\ samples injected (Waters Intelligent Sample Processor 710B) directly onto a reverse-phase, 5-^m C-18 HPLC column (Beckman). A linear gradient at a flow of 1.1 ml/min over 25 minutes was used, with initial conditions of 90% 4 mM KH 2 PO 4 638 and 10% 70/30 methanol/water (vol/vol). Final conditions were 70% 4 ITIM KH 2 PO 4 and 30% 70/30 methanol/ water (vol/vol). Absorbance of the column eluate was continuously monitored at 254 nm (Waters model 440 absorbance detector) and recorded with a Waters data module. Peaks were identified by comparison with retention times of external standards and were verified by treating intermittent duplicate samples with adenosine deaminase or nucleoside phosphorylase. Adenosine and inosine were quantified by determining the area under the absorbance peak and comparing it to standards. This procedure resulted in >90% recovery of adenosine and inosine when known quantities were added to samples of coronary effluent. Regarding adenosine, this recovery was attained with or without the presence of the adenosine deaminase inhibitor, erythro-9-(2-hydroxy-3-nonyl) adenine (EHNA) in the tubes used to collect the coronary effluent fractions.
Statistical Analysis
Results are expressed as the mean ± SEM. Homogeneity of variances among means was established for statistical analysis by transformation of raw data (i.e., log (Y + 1)) (Sokal and Rohlf, 1981) . We used one-way analysis of variance and Student-Neuman-Keuls test for multiple comparisons between mean data (Sokal and Rohlf, 1981) to compare values of coronary flow, oxygen consumption, or release of purines against time. Mixed model analysis of variance (Linton and Gallo, 1975) and Student-Neuman-Keuls test for multiple comparisons between mean data were used to compare responses to treatments (i.e., norepinephrine vs. norepinephrine + prazosin vs. isoproterenol vs. norepinephrine + propranolol). Differences between mean data were considered significant at P < 0.05.
Results
In the first series of experiments (Fig. 1) , eight guinea pig hearts had a control coronary flow of 7.5 ± 0.4 ml/min per g, an MVO 2 of 85 ± 5 fi\ O 2 /min per g, and an adenosine release of 22 ± 5 pmol/ min per g. In four of these animals, control inosine release was 431 ± 3 9 pmol/min per g (Table 1 ). When norepinephrine was infused (6 X 10" 10 mol/ min), coronary flow decreased during the first 15-30 seconds but then increased significantly to 10.6 ± 0.4 ml/min per g by 1 minute. In addition, MVO 2 and adenosine release significantly increased to maximal levels of 125 ± 9 ^1 02/min per g and 849 ± 1 1 0 pmol/min per g, respectively, by 1 minute. Inosine release attained a maximal level of 2595 ± 581 pmol/min per g by 2 minutes. After 1 minute, coronary flow and MVO2 values were sustained. In contrast, adenosine and inosine release significantly declined to nadirs by 9.5 minutes. Thereafter, steady state levels of 117 ± 24 and 960 ± 294 pmol/min per g, respectively, were maintained; these levels were significantly elevated above their control values.
In the second series of experiments, we infused norepinephrine (6 X 10~1 0 mol/min) into four hearts for 11 minutes. We then infused adenosine (1 x 10~5 mol/min) along with norepinephrine for 7 minutes. After 5 minutes of adenosine infusion, coronary flow increased from 8.9 ± 0.4 ml/min per g to 15.8 ±1.2 ml/min per g. In four other hearts (Table 2) , we infused norepinephrine at 6 X 10~1 0 mol/min for 11 minutes and then at 3 X 10~9 mol/ min for 11 minutes. During the latter infusion, all variables attained higher values. However, adenosine release was phasic during both infusions, despite an elevated, unchanging coronary flow and MVO2. In the last protocol, we exposed four hearts (Table 3) to a constant perfusate concentration of norepinephrine (6 X 10 mol/liter). The responses to the constant concentration were essentially identical to the norepinephrine infusion experiments, except that they were delayed by about 1 minute. Norepinephrine was infused into the aortic cannula at a rate of 6 X 10~1 0 mol/min (steady state concentration = 6 X 10"' M). Coronary effluent was serially sampled over 30-second periods. Times listed are the endpoints of each sampling period. Values are mean ± SEM (n = A).
* P < 0.05 vs. control.
•f P < 0.05 vs. peak value Coronary flow (rru/min per g) 6.9 ± 0.5 9.8 ± 0.5* 9.9 ±0.5* 10.4 ± 0 4* 12.3 ± 0.3f 12.8 ± 0.4t 13.2 ± 0 2f Infusion of norepinephrine (NE) at two delivery rates for 11 minutes (steady state concentrations: 6 X 10~8 M NE and 7 X 10~7 M NE). Coronary effluent was serially sampled over 2-minute periods. Times listed are the midpoints of each sampling period. Values are mean ± SEM, (n = 4).
• P < 0.05 vs. control. t P < 0.05 vs. low dose. j P < 0.05 vs. 3-minute value.
In the third series of experiments, we exposed five hearts (Fig. 2) to a-receptor blockade with prazosin before and during norepinephrine infusion. The response to prazosin (3 X 10 mol/min) infusion was a small reduction in MVO2, but no change in coronary flow or adenosine release. The only difference between the responses to norepinephrine, with and without prazosin, was that the initial vasoconstriction seen with norepinephrine, alone, was abolished by prazosin. In five other hearts, the responses to infusion of isoproterenol (3 X 10" 11 mol/min) were identical to those observed with a-blockade during norepinephrine infusion (i.e., steady state coronary flow = 12.2 ± 0.7 ml/min per g, MVO 2 = 150 jtl O2/min per g, adenosine release at 1 minute = 945 ± 78 pmol/min per g, adenosine release at 11 minutes = 56 ± 10 pmol/min per g). Finally, the responses to propranolol in five hearts (Fig. 3) were a decrease in MVO2, an increase in coronary flow, but no change in adenosine release. Infusion of norepinephrine, in the presence of propranolol, resulted in sustained vasoconstriction, and no change in MVO2 or adenosine release.
In the last series of experiments, five hearts (Fig.  4) were exposed to an elevated calcium concentration (8.1 mM). Coronary flow, MVO 2 , and adenosine release significantly increased to maximal values within 2 minutes; thereafter, MVO 2 and flow were sustained while adenosine release declined to levels not significantly different from control. Infusion of propranolol (2 X 10~7 mol/min) during exposure to elevated calcium (Table 4) , in five other hearts, yielded qualitatively similar results.
Discussion
The major findings of this study may be summarized as follows. When guinea pig hearts are exposed Exposure to a concentration of norepinephrine (NE) equal to that attained at 6 minutes during infusion of NE. Coronary effluent was serially sampled over 30-second periods. Times listed are the endpoints of each sampling period. The adenosine response is not significantly different from infusion of NE. Values are mean ± SEM (n = 4). * P < 0.05 vs. control. f P < 0.05 vs. 2-minute value. to catecholamines or elevated perfusate calcium concentration, there is a significantly increased myocardial oxygen consumption, coronary flow, and adenosine release (Figs. 1, 2 , and 4; Table 3 ). Adenosine release subsequently declines to a significantly lower level that is sustained after 9.5 minutes. With catecholamine administration, the 9.5-minute levels are still elevated above control values; however, with exposure to elevated calcium, the 9.5-minute adenosine release is not significantly different from control. Despite the significant attenuation of adenosine release, elevated coronary flow and myocardial oxygen consumption remained unchanged. These results raise a question concerning the extent of adenosine's participation in sustained metabolic dilation of the coronary bed. 
TIUE (mlnutta)
12 FIGURE 3. Effect of an 11-minute infusion of norepmephrine (6 x JO" 10 mol/min) during infusion of propranolol (2 x 10~7 mol/min) on coronary flow, myocardial oxygen consumption (MVO-i), and adenosine release (n = 5). Pulmonary artery effluent Pen was continuously monitored with an inline oxygen electrode and measurements were obtained at 20-second intervals during the first 3 minutes and at 6.5, 9.5, and 11 minutes. Perfusate P02 was measured during control and at 12 minutes. All other variables were determined and plotted as described in Figure 1 . There are several advantages to using isolated hearts in our study. (1) The effects of pharmacological agents can be determined in the absence of plasma borne humoral and neural influences. (2) The use of crystalloid-perfusate, rather than blood, simplifies measurements of adenosine and inosine, making it feasible to study the time course of purine release. In addition, the enzymatic degradation of adenosine that occurs in blood, and erythrocyte uptake of these compounds are absent. (3) The perfusate is of known composition, is devoid of adenosine and inosine, and is not recirculated. Therefore, computations of net release of purines represent true release from the myocardium into the vascular space.
There are potential disadvantages associated with the use of an in vitro, crystalloid-perfused heart as a model of the intact system. However, for the purposes of this study, the preparation exhibits the pertinent features of an intact, blood-perfused heart. Spontaneous heart rate and myocardial oxygen consumption are stable for up to 3 hours; this exceeds the time period during which the hearts included in these experiments were studied. The coronary bed exhibits autoregulation of flow, and transient occlusion of arterial inflow results in a 2-to 3-fold increase in coronary flow (reactive hyperemia). We believe these hearts are adequately oxygenated because they release no more adenosine than do blood perfused dog hearts under basal conditions (Manfredi and Sparks, 1982) . Oxygen extraction and coronary flow are not maximal, as evidenced by the increases exhibited during periods of increased metabolism.
A possible weakness of this study is the use of adenosine release as an index of interstitial, or perivascular adenosine. Previous studies of metabolic coronary vasoregulation have used other indices of interstitial adenosine, e.g., the rate of adenosine accumulation in an artificial pericardial infusate (Miller et al., 1979) . There are problems with this index of interstitial adenosine concentration, and 1682 ± 799* 767 ± 289' 362 ± 150*t 77 ± 9 | 61 ± 12f 59 ± 14f
Infusion of propranolol before and during elevation of perfusate calcium concentration (steady state concentration of propranolol during exposure to elevated calcium = 2 x 10~5 M). Coronary effluent was serially sampled over 30-second periods. Times listed are the endpoints of each sampling period. Exposure to propranolol did not significantly alter the response to elevation of perfusate calaum Values are mean ± SEM (n = 4).
* P < 0 05 vs control. f P < 0.05 vs. 1-minute value.
they have been discussed elsewhere (Kusachi and Olsson, 1983) . We feel that adenosine release into the vascular space is more likely to be sensitive to transients and should represent a global index of interstitial adenosine, because all myocardial regions contribute to the venous effluent. Other investigators have used tissue levels of adenosine as an index of the interstitial concentrations (Foley et al., 1978; McKenzie et al., 1980; Saito et al., 1980) . However, accumulating evidence suggests that adenosine may exist, not only in the interstitial space, but intracellularly as well (Schrader and Gerlach, 1976; Olsson et al., 1978; Schrader et al., 1981; Schutz et al., 1981) . Such an intracellular pool would complicate the interpretation of tissue measurements of adenosine. Conversely, adenosine release should have no direct dependence on changes in the size of intracellular bound pools. Catecholamine infusions or catecholamine release from endogenous stores (via sympathetic stimulation) have been used in order to study the relationship between adenosine production and myocardial perfusion during augmented myocardial metabolism. The adenosine concentration of the myocardium (Foley et al., 1978; McKenzie et al., 1980; Saito et al., 1980) , or pericardial infusate (Watkinson et al., 1979; Miller et al., 1979) was found to increase significantly in parallel with increasing coronary flow. Adenosine release into the coronary effluent has been measured during infusions of isoproterenol (Schrader et al., 1977c) and norepinephrine (Wiedmeier and Spell, 1977; Manfredi and Sparks, 1982) . Again, a positive correlation was found between coronary flow and adenosine release. However, Jones et al., (1982) found that when aminophylline was administered to dog hearts, at levels sufficient to block vasodilation elicited by adenosine infusion, norepinephrine-induced hyperemia was not reduced. None of these studies reported the dynamics of the relationship between coronary flow and adenosine. Instead, the tissue content of adenosine was determined at a single time point, or the coronary effluent concentration was measured either at a single time point or as an integral of a 5-to 15-minute collection period. If adenosine couples myocardial metabolism and perfusion, then the time course for changes in these variables should be parallel. Our results show that coronary flow and adenosine release follow dissimilar time courses.
Two studies have examined the early time course of coronary effluent adenosine concentration during catecholamine stimulation. Schrader et al., (1981) infused isoproterenol (effective concentration: 3 X 10~7 M) into isolated guinea pig hearts and measured the adenosine content of the coronary effluent at 15-second intervals for 4 minutes. Coronary flow and adenosine concentration changed in parallel during the first minute. During the subsequent 3 minutes, there was a slight decline in adenosine concentration. In our study, we infused isoproterenol that produced an effective steady state concentration of 3 x 10" 9 M, and we observed phasic release of adenosine. When we infused larger amounts of norepinephrine (effective concentration: 7 X 10~7 M) (Table 2), we found that the peak release of adenosine was sustained throughout the first 6 minutes and the phasic pattern was only evident thereafter.
In constant flow-perfused, isolated rabbit hearts, Fredholm et al., (1982) measured the coronary venous effluent concentration of adenosine, at 1-minute intervals, during 3-minute infusions of norepinephrine. Their results reveal a phasic pattern of venous adenosine concentration; however, they did not address this observation.
There are several potential explanations for the phasic pattern of adenosine release which we have observed. First, the adenosine released during the first 10 minutes of norepinephrine stimulation may reflect a supramaximal interstitial fluid concentration of the nucleoside; thus, the release is more than is necessary to elicit maximal vasodilation. This is ruled out by the observation that infusion of adenosine during norepinephrine infusion results in a further increase in coronary flow. This would not have occurred if the concentration of adenosine already present was supramaximal. Second, the decline in adenosine and inosine release during norepinephrine infusion may reflect substrate depletion. However, this is inconsistent with the observation that an augmented delivery of norepinephrine accentuates the release of adenosine (Table 2) . Third, the phasic nature of adenosine release could result from increased degradation of adenosine to inosine. This is unlikely because inosine has a time course similar to that of adenosine (Table 1) . Fourth, the phasic release of adenosine, during infusion of catecholamines, could be due to a decreasing concentration of agonist. This would result from a constant infusion rate of catecholamine during an increasing coronary flow. However, exposure to a constant concentration of norepinephrine (Table 3) or elevated calcium (Fig. 4) results in phasic release of adenosine. Finally, the initial elevation of adenosine release during norepinephrine infusion may be the result of transient a-receptor, mediated vasoconstriction. This mechanism could result in a brief episode of ischemia following the onset of infusion. However, such an explanation is not consonant with the observations that a-receptor blockade with prazosin eliminated the vasoconstricrion, but not the phasic release of adenosine during norepinephrine infusion, and infusion of isoproterenol or elevation of calcium concentration resulted in responses identical to those seen with norepinephrine.
The relevance of these results to the adenosine hypothesis depends on the assumption that the concentration of adenosine in the coronary effluent is related to its interstitial concentration. It is likely that adenosine diffuses through the capillary wall via water-filled, interendothelial clefts. If this is true, the transcapillary flux of adenosine is then determined by the perfusate concentration of adenosine, adenosine degradation within interendothelial clefts, endothelial uptake of plasma adenosine, the capillary permeability-surface area product, and the interstitial adenosine concentration. The question is, which of these variables could cause the decline in adenosine release during metabolic stimulation. As pointed out earlier, the perfusate is not recirculated, and adenosine is not present in the perfusate. Thus, changes in arterial adenosine concentration could not be responsible for a decline in adenosine release. The decline could be explained by enhanced adenosine uptake or degradation by the endothelium. However, we are aware of no evidence supporting the idea that a time-related increase in endothelial uptake could occur. Although the effect of catecholCirculation Research/Vol. 53, No. 5, November 1983 amine and elevated calcium on coronary permeability to adenosine is unknown, it would seem unlikely that vascular permeability or surface area would change under the steady state conditions during which adenosine release was decreasing. Thus, of the five determinants of transvascular adenosine flux, the first four cannot readily explain the phasic pattern of adenosine release. The most likely explanation resides in the single remaining determinantinterstitial adenosine concentration.
Another possibility is that endothelial cells release adenosine upon stimulation with catecholamines or calcium. If this occurs, then release of adenosine is not a good measure of interstitial adenosine levels. However, there is no evidence that these agonists can elicit such a massive release of purines from endothelial cells.
In view of these considerations, we think that the most likely interpretation of our measurements of adenosine release is that interstitial adenosine concentration declines in the presence of unchanging metabolic vasodilation associated with administration of catecholamines or elevated calcium. This is not the first reported occurrence of a phasic release of a vasodilator in the heart. We have shown in an earlier study that there is phasic release of potassium when myocardial metabolism is increased (Murray et al., 1979) . However, the release of potassium could account for only approximately onethird of the resultant vasodilation. Clearly, adenosine could account for the remainder of the initial vasodilation.
Our results show that adenosine release is phasic during several conditions in which oxygen consumption and coronary flow are elevated and in a steady state. Our interpretations are that (1) during prolonged periods of increased metabolism, purine conservation mechanisms may be brought into play, and (2) there is major participation by another metabolic mediator during sustained coronary dilation.
